What the largest real-world study found about durability
The most comprehensive evidence comes from a 2025 systematic review that pooled data from six studies covering 12,731 people who received psychedelic-assisted therapy at home, supported by digital tools like telehealth and mobile apps [1]. The review found high response rates for depression—between 56.4% and 62.8%—meaning more than half of patients saw meaningful improvement. Symptoms improved rapidly, especially for depression and anxiety. But the review also flagged serious safety issues: one unintentional overdose and several psychiatric adverse events. The authors rated the risk of bias as moderate to serious across the non-randomized studies, which means we can't be fully confident in the durability claims. In plain terms: the therapy can work well for many people, but the evidence isn't rock-solid yet, and safety monitoring is critical.
Why the therapist matters more than the drug for lasting change
The same 2022 paper also notes that psychological flexibility—the ability to adapt thoughts and behaviors—was a better predictor of long-term outcome than the intensity of the mystical experience itself [4]. This means that durable improvement isn't about having a single life-changing trip; it's about what you do before and after. The paper describes a 48-year-old man with long-standing depression whose symptoms returned quickly after his first ketamine session, but then improved durably once he combined neurofeedback training with subsequent sessions. This pattern—rapid initial relief, then relapse, then durable improvement with added support—is a common theme across the evidence.
The catch: safety concerns and weak study designs
While the results are promising, the evidence has real limitations. The largest review [1] found that all six included studies were non-randomized, meaning they didn't compare the therapy against a placebo or standard treatment. This makes it hard to know how much of the improvement is due to the psychedelic versus the therapy, or just the passage of time. The review also documented serious safety events, including one unintentional overdose and psychiatric adverse events, which underscore the need for strict oversight—especially in at-home, digitally enabled settings. A 2023 commentary [5] describes psychedelic treatments as opening an 'unparalleled window of opportunity' but stresses that we need to get ready for their roll-out, implying the infrastructure for safe, durable treatment isn't fully in place yet. A 2024 feature story [3] echoes this, noting that the expansion of psychedelic treatments raises complex ethical and accessibility questions. In short: the therapy can produce durable improvements, but the current evidence base is too weak to guarantee that outcome for everyone, and safety must be the top priority.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2022 to 2025, 3 from 2024 or later, 1 in Q1 journals — selected as the most relevant from 5 studies that passed quality screening, drawn from 41 papers retrieved from a database of over 500 million.
Sources used in this answer
Digital Enablement of Psychedelic-Assisted Therapy in Non-Clinical Settings: A Systematic Review of Safety, Efficacy, and Implementation Models
A 2025 systematic review of 12,731 participants across six studies found high response rates (56.4-62.8% for depression) with rapid symptom improvement in digitally enabled at-home psychedelic therapy, but also documented serious safety concerns including psychiatric adverse events and one unintentional overdose, with moderate-to-serious risk of bias across non-randomized studies.
Patient–therapist relationship in psychedelic-assisted therapy: Implications for future real-world settings
A 2025 analysis argues that the patient-therapist relationship is crucial for therapeutic and ethical reasons in psychedelic-assisted therapy, and warns that cost-cutting measures like shortening preparation phases risk undermining this relationship and thus the durability of improvements.
The New Horizon of Psychedelic Treatment for Mental Health
A 2024 feature story on psychedelic treatments in Montana explores the promise and problems of wider availability, including legality, ethics, accessibility, and who should or should not use these treatments, based on interviews with clinic owners and patients.
SPECIAL ISSUE: Do Biofeedback, Neurofeedback, and Neuromeditation Have a Role in Psychedelic-Assisted Therapies?
A 2022 paper describes how biofeedback, neurofeedback, and neuromeditation can be used in the preparation and integration phases of psychedelic-assisted therapy to enhance psychological flexibility, citing case examples where symptoms returned after initial psychedelic sessions but improved durably with added technology-based training.
Brain health conditions: Excellence in psychedelic treatments
A 2023 commentary states that psychedelic-assisted therapies, combined with proper psychosocial support, hold the potential to provide safe, rapid-acting, and robust clinical improvements with durable effects, but emphasizes that healthcare systems need to prepare for their roll-out.